Natalizumab: targeting alpha4-integrins in multiple sclerosis.
about
Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castleHuman polyomavirus reactivation: disease pathogenesis and treatment approachesLive cell imaging techniques to study T cell trafficking across the blood-brain barrier in vitro and in vivoMolecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brainAdhesion molecules in CNS disorders: biomarker and therapeutic targetsAnalysis of behavior and trafficking of dendritic cells within the brain during toxoplasmic encephalitisIdentification of an essential endogenous regulator of blood-brain barrier integrity, and its pathological and therapeutic implicationsPolymorphisms in the α4 integrin of neotropical primates: insights for binding of natural ligands and HIV-1 gp120 to the human α4β7Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitisCharacteristics and critical function of CD8+ T cells in the Toxoplasma-infected brain.Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Use of natalizumab in multiple sclerosis: current perspectives.Effects of natalizumab treatment on Foxp3+ T regulatory cells.Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuationEfficacy and side effects of natalizumab therapy in patients with multiple sclerosis.Trafficking of immune cells in the central nervous systemIntegrin Targeted MR Imaging.Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy.Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrierFingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis.Engaging neuroscience to advance translational research in brain barrier biology.Monocyte trafficking across the vessel wallSLAT promotes TCR-mediated, Rap1-dependent LFA-1 activation and adhesion through interaction of its PH domain with Rap1.Mechanisms and insights into drug resistance in cancerNew insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.Current and future therapies for multiple sclerosis.Tight junction proteins expression and modulation in immune cells and multiple sclerosis5-HT2 receptors facilitate JC polyomavirus entry.DARC shuttles inflammatory chemokines across the blood-brain barrier during autoimmune central nervous system inflammation.Immunomodulatory drug treatment in multiple sclerosis.Review: leucocyte-endothelial cell crosstalk at the blood-brain barrier: a prerequisite for successful immune cell entry to the brain.Integrins as receptor targets for neurological disordersNew findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis.The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis.Monoclonal antibodies in treatment of multiple sclerosis.Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.
P2860
Q21195861-0DA90BE0-C5E6-4CFE-B5C6-2AC5B6B1CEE5Q21285083-05A6AC42-7727-4A64-8E64-973E0C942E9CQ22001136-671B99DC-4432-42F2-B571-C4F70B29DFC5Q24619923-6DF43496-B310-4FDC-B338-3E6E102CAE19Q27015967-27335FD2-038E-46C4-8433-2A3217B3686EQ27349006-96DE2942-9837-437D-9D15-38613A25EF79Q28282373-DE82CDD8-BAD3-4E38-8170-E537B2AD04EEQ28476793-8A349DB6-939F-4CCD-88A4-210BECA9A181Q28588370-10591E99-24FD-4E32-9A01-CF27ACF4CBFAQ30354096-6BBCFE72-4840-4D61-992A-B2F1DEB6AFB2Q30699740-593B84B6-DDC9-486E-9B43-982A1CC86984Q31114633-E4793323-3D5F-4C42-A570-19F2A5629EC7Q33373995-2755D828-C410-4318-B8B5-58C4C44C9B6CQ33562198-B3EA078B-C86B-4243-A2BF-7B800E4CA34CQ33573208-42A8591D-60A1-45FB-A174-19C0ADD38419Q33815795-804FAB0B-6959-4F80-9883-B9F3D540DFA0Q33890945-0C1BE037-9304-4CF8-9CDD-3C046CD0097FQ34110804-BF0BB12F-A210-428E-9F73-CFDD08D936E3Q35136280-3B76BB31-99A1-4DAA-B3EB-DCFA3E1D661FQ35578146-40B5680E-A50A-4841-835C-061BF11F61B1Q35675602-47E992AC-6FB9-4E74-A2C7-25A8C6E02AD9Q35762032-4C7DAA04-AC85-4B3E-8BDE-3D49950511CBQ35909313-17A3B8AF-BD9B-498E-86A8-46B108458372Q36117359-543DE1DC-75B2-4542-8E81-FC9E85C95086Q36462445-914BA7CC-939E-468E-A48F-7D4283657E1AQ36682301-BC95A479-1541-4950-B56A-91F16433BE34Q37045253-8C06E1DF-8671-439E-BDD5-1D13B654AD95Q37287769-25D4C277-E530-4166-A3C7-C1CBC3279991Q37294615-1AA12A95-931D-4F4E-8E00-6F2CFAEBEB0AQ37336799-5C65613E-46EA-459B-BE1D-84CD179A4DB1Q37723420-500F2293-F350-431C-BBF9-C2B88AEF4FFFQ37785554-1F0F8828-AF6C-4B22-A894-9AE917F5A971Q37800163-E12EF8F4-38F9-4103-971E-CE441B047941Q37974737-C0AC4AD4-2C00-4C60-9497-6595266F8C34Q38103283-BB1AF6D8-91CB-4F22-A2E3-CCF9616DA159Q38115525-829399F4-E8B3-401C-99B6-690EBFABD8AFQ38133865-2FA98ABE-D0F4-4541-845B-306D53E6D8AFQ38150405-F40091D3-5311-4998-AD9E-D3133E32878BQ38252979-57599394-8A4D-41B2-A96E-5D703031ED2CQ38286209-E495161C-636F-4156-926A-8A601CE086C9
P2860
Natalizumab: targeting alpha4-integrins in multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Natalizumab: targeting alpha4-integrins in multiple sclerosis.
@en
Natalizumab: targeting alpha4-integrins in multiple sclerosis.
@nl
type
label
Natalizumab: targeting alpha4-integrins in multiple sclerosis.
@en
Natalizumab: targeting alpha4-integrins in multiple sclerosis.
@nl
altLabel
Natalizumab: Targeting α<sub>4</sub>-Integrins in Multiple Sclerosis
@en
prefLabel
Natalizumab: targeting alpha4-integrins in multiple sclerosis.
@en
Natalizumab: targeting alpha4-integrins in multiple sclerosis.
@nl
P2860
P356
P1476
Natalizumab: targeting alpha4-integrins in multiple sclerosis.
@en
P2093
Britta Engelhardt
P2860
P356
10.1159/000109933
P577
2008-01-01T00:00:00Z